Drotrecogin alfa (activated) in severe sepsis--authors' reply

Comment

Andre C Kalil et al. Lancet Infect Dis. 2013 Feb.

. 2013 Feb;13(2):110-1.

doi: 10.1016/S1473-3099(12)70350-X.

Erratum in

No abstract available

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC, LaRosa SP. Kalil AC, et al. Lancet Infect Dis. 2012 Sep;12(9):678-86. doi: 10.1016/S1473-3099(12)70157-3. Epub 2012 Jul 17. Lancet Infect Dis. 2012. PMID: 22809883
Drotrecogin alfa (activated) in severe sepsis.
Poole D, Rossi C, Addis A, Livigni S, Bertolini G. Poole D, et al. Lancet Infect Dis. 2013 Feb;13(2):107-8. doi: 10.1016/S1473-3099(12)70325-0. Lancet Infect Dis. 2013. PMID: 23347624 No abstract available.
Drotrecogin alfa (activated) in severe sepsis.
Marik PE. Marik PE. Lancet Infect Dis. 2013 Feb;13(2):107. doi: 10.1016/S1473-3099(12)70311-0. Lancet Infect Dis. 2013. PMID: 23347625 No abstract available.
Drotrecogin alfa (activated) in severe sepsis.
Janes JM, Vangerow B, Costigan TM, Macias WL. Janes JM, et al. Lancet Infect Dis. 2013 Feb;13(2):108-9. doi: 10.1016/S1473-3099(12)70309-2. Lancet Infect Dis. 2013. PMID: 23347626 No abstract available.
Drotrecogin alfa (activated) in severe sepsis.
Gayat E, Lemasle L, Payen D. Gayat E, et al. Lancet Infect Dis. 2013 Feb;13(2):109-10. doi: 10.1016/S1473-3099(12)70269-4. Lancet Infect Dis. 2013. PMID: 23347627 No abstract available.